Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 65,15 € (+28,73%). Mediana wynosi 69,21 € (+36,75%).
| Kupuj |
12 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
BrightSpring Health Services expects broad growth and strong cash flow profile
At the Jefferies conference BrightSpring Health Services presented a diversified growth model focused on specialty pharmacies, home health and hospice services. Management is targeting EBITDA growth of 15–20% over the next two years and expects operating cash flow of more than US$600 million for 2026 and roughly US$500 million of free cash flow (excluding the tax impact of the Community‑Living divestiture). Leverage could fall below 2.0x by year-end, creating room for acquisitions, share buybacks or dividends. Continued growth drivers include generic drug switches, exclusive medication partnerships, technology and AI deployments, and further consolidation opportunities in the home health market. » Więcej na de.investing.com
BrightSpring accelerates growth in pharmacy and provider businesses
BrightSpring presented at the Wells Fargo Healthcare Conference a markedly accelerated EBITDA growth in the pharmacy segment (near 40% in 2025, >40% in H1 2026) and about 20% organic EBITDA growth in the provider business, supported by the integration of Amedisys LHC. Management highlighted investments in automation, AI and M&A as well as reduced leverage (near 2x EBITDA), which creates room for further acquisitions. The company expects 2026 to see the largest headwinds from IRA drug-price negotiations (around $15 million EBITDA impact), with a much smaller effect in 2027, and sees long-term tailwinds from LDD contracts, generic switches and expansion in the infusion and services business. » Więcej na de.investing.com
Secondary placement weighs on BrightSpring Health Services
Shares of BrightSpring Health Services fell about 4.4% in after-hours trading after the announcement of a secondary placement of 15 million common shares by existing shareholders, including a subsidiary of Kohlberg Kravis Roberts and members of management. BrightSpring itself is not selling any shares and will not receive proceeds from the placement. At the same time, the company approved a share buyback of up to $60 million (up to 10% of the sold shares), to be executed concurrently with the placement; Goldman Sachs is acting as sole book-running manager. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 3,39 mld | 27,08% |
| Zysk brutto | 431,75 mln | 35,76% |
| Zysk netto | 75,95 mln | 217,37% |
| EBITDA | 162,99 mln | 112,52% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 9,97 mld € |
Liczba akcji | 196,26 mln |
Maksimum/minimum z 52 tygodni | 63,80 € - 22,43 € |
| Dywidendy | Nie |
Beta | 1,85 |
C/Z (PE Ratio) | 41,07 |
PEG (PEG Ratio) | 0,12 |
C/WK (PB Ratio) | 5,91 |
C/S (PS Ratio) | 0,80 |
Profil spółki
BrightSpring Health Services, Inc. betreibt eine Plattform für häusliche und gemeindenahe Gesundheitsdienste in den Vereinigten Staaten. Die Plattform des Unternehmens konzentriert sich auf die Bereitstellung von Apotheken- und Anbieterdiensten, einschließlich klinischer und unterstützender Pflege in häuslicher und kommunaler Umgebung für Medicare-, Medicaid- und versicherte Bevölkerungsgruppen. Die Betreuung der Patienten erfolgt durch klinische Anbieter und Apotheker. BrightSpring Health Services, Inc. war früher als Phoenix Parent Holdings Inc. bekannt und änderte im Mai 2021 seinen Namen in BrightSpring Health Services, Inc. Das Unternehmen wurde 1974 gegründet und hat seinen Sitz in Louisville, Kentucky.
| Nazwa | BrightSpring Health Services Inc |
| CEO | Jon Rousseau |
| Siedziba | Louisville,
ky Stany Zjednoczone |
| Strona internetowa | |
| Branża | Ochrona zdrowia: świadczeniodawcy i usługi |
| Debiut giełdowy | 26.01.2024 |
| Pracownicy | 23 500 |
Deep Dive
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | BTSG |